Cancer cells suppress NK cell activity by actin-driven polarization of inhibitory ligands to the immunological synapse
Abstract
Natural killer (NK) cells engage target cells via the immunological synapse (IS), where inhibitory and activating signals determine whether NK cell cytotoxicity is suppressed or activated. We previously reported that cancer cells can rapidly remodel their actin cytoskeleton upon NK cell engagement, leading to F-actin accumulation at the synapse. Here, we show that this process inhibits NK cell activation as indicated by impaired MTOC and lytic granule polarization. Exploring the underlying mechanism, we demonstrate that actin remodeling drives the recruitment of inhibitory ligands, such as HLA-A, -B, and -C, to the synapse. Disrupting HLA interaction with their cognate inhibitory receptors KIRs restores NK cell activation. Using NK cells expressing inhibitory KIR receptors, matched or unmatched to HLA molecules on cancer cells, we show that synaptic F-actin accumulation and matching KIR–HLA interactions jointly suppress NK cell cytotoxicity. Our findings reveal an immune evasion strategy in which cancer cells impair NK cell activation by altering synaptic signaling through actin cytoskeleton–driven recruitment of inhibitory signals to the IS.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (9)
Céline Hoffmann
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Liza Filali
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Hannah Wurzer
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Diogo Pereira Fernandes
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Takouhie Mgrditchian
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Wanxin Huang
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Flora Moreau
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Max Krecké
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health
Clément Thomas
Cytoskeleton and Cancer Progression, Department of Cancer Research, Luxembourg Institute of Health